
  
    
      
        Introduction_NNP
        HIV_NNP infection_NN is_VBZ currently_RB the_DT third_JJ leading_VBG cause_NN of_IN
        death_NN in_IN women_NNS ages_NNS 25_CD -_: 44_CD years_NNS [_NN 1_CD ]_NN and_CC manifestations_NNS of_IN
        HIV_NNP infection_NN show_NN important_JJ gender-dependent_JJ differences_NNS ._.
        Women_NNP frequently_RB develop_VBP menstrual_JJ abnormalities_NNS with_IN
        amenorrhea_NN ,_, and_CC manifestations_NNS of_IN AIDS_NNP occur_VB at_IN higher_JJR CD_NNP 4_CD
        counts_VBZ and_CC lower_JJR viral_JJ load_NN as_IN compared_VBN to_TO men_NNS [_NN 2_CD ]_NN ._. Plasma_NNP
        estradiol_NN levels_NNS are_VBP also_RB lower_JJR in_IN HIV-infected_NNP women_NNS [_NN 3_CD ]_NN ._.
        It_PRP remains_VBZ unclear_JJ if_IN dementia_NN associated_VBN with_IN HIV_NNP
        infection_NN occurs_VBZ more_RBR frequently_RB in_IN women_NNS than_IN men_NNS ._. A_DT large_JJ
        multicenter_NN European_JJ study_NN showed_VBD that_IN women_NNS were_VBD twice_RB as_IN
        likely_JJ to_TO develop_VB HIV_NNP dementia_NN compared_VBN to_TO men_NNS [_NN 4_CD ]_NN ;_:
        however_RB ,_, another_DT study_NN failed_VBD to_TO confirm_VB these_DT differences_NNS
        [_NN 5_CD ]_NN ._.
        Drug_NN abuse_NN accounts_NNS for_IN nearly_RB half_NN of_IN the_DT HIV_NNP
        infections_NNS in_IN women_NNS in_IN United_NNP States_NNPS [_NN 1_CD ]_NN ,_, however_RB ,_, the_DT
        effect_NN of_IN drug_NN abuse_NN on_IN incidence_NN ,_, rate_NN of_IN progression_NN or_CC
        severity_NN of_IN HIV_NNP dementia_NN is_VBZ not_RB entirely_RB clear_JJ ._. Although_IN no_DT
        major_JJ differences_NNS were_VBD noted_VBN in_IN cognitive_JJ functioning_NN
        amongst_IN HIV-infected_NNP asymptomatics_NNS with_IN or_CC without_IN a_DT
        history_NN of_IN drug_NN abuse_NN [_NN 6_CD ]_NN ,_, a_DT subsequent_JJ study_NN showed_VBD that_IN
        a_DT history_NN of_IN injection_NN drug_NN use_NN and_CC presentation_NN with_IN
        prominent_JJ psychomotor_NN slowing_VBG was_VBD associated_VBN with_IN more_RBR
        rapid_JJ neurologic_JJ progression_NN [_NN 7_CD ]_NN ._. Other_JJ neuropathological_JJ
        studies_NNS show_NN marked_VBD sever_VB ity_NN of_IN HIV_NNP encephalitis_NNS in_IN drug_NN
        abusers_NNS [_NN 8_CD ]_NN particularly_RB involving_VBG loss_NN of_IN dopaminergic_JJ
        neurons_NNS [_NN 9_CD ]_NN ._. Long_JJ term_NN methamphetamine_NN use_NN has_VBZ also_RB been_VBN
        associated_VBN with_IN neuronal_NN damage_NN as_IN determined_VBN by_IN magnetic_JJ
        resonance_NN spectroscopy_NN brain_NN imaging_NN studies_NNS [_NN 10_CD ]_NN ._. Autopsy_NNP
        studies_NNS also_RB confirm_VBP injury_NN to_TO dopaminergic_JJ neurons_NNS in_IN
        cocaine_NN as_RB well_RB or_CC methamphetamine_NN abusers_NNS [_NN 11_CD ,_, 12_CD ]_NN ._.
        Interestingly_RB ,_, some_DT investigators_NNS have_VBP proposed_VBN the_DT use_NN of_IN
        psychostimulants_NNS in_IN the_DT treatment_NN of_IN HIV_NNP dementia_NN [_NN 13_CD ]_NN ,_,
        however_RB the_DT effects_NNS of_IN these_DT drugs_NNS on_IN cerebral_JJ function_NN in_IN
        the_DT setting_NN of_IN HIV_NNP infection_NN has_VBZ not_RB been_VBN well_RB studied_VBN ._.
        HIV_NNP proteins_NNS gp_NN 120_CD and_CC Tat_NNP have_VBP been_VBN implicated_VBN in_IN the_DT
        neuropathogenesis_NNS of_IN HIV_NNP dementia_NN ._. Both_DT proteins_NNS are_VBP
        released_VBN from_IN HIV_NNP infected_JJ cells_NNS and_CC are_VBP present_JJ in_IN the_DT
        brains_NNS of_IN HIV_NNP infected_VBN patients_NNS with_IN dementia_NN or_CC
        encephalitis_NNS [_NN 14_CD ]_NN ._. Recent_JJ studies_NNS from_IN our_PRP$ laboratory_NN have_VBP
        shown_VBN that_IN these_DT proteins_NNS cause_VBP synergistic_JJ neurotoxicity_NN
        that_WDT involves_VBZ excitatory_NN amino_JJ acid_NN receptors_NNS and_CC oxidative_JJ
        pathways_NNS [_NN 15_CD ]_NN ._.
        Estrogen_NNP deficiency_NN has_VBZ been_VBN implicated_VBN as_IN a_DT risk_NN factor_NN
        in_IN the_DT development_NN of_IN several_JJ neurodegenerative_JJ diseases_NNS [_NN
        16_CD ,_, 17_CD ,_, 18_CD ]_NN and_CC estrogen_NN replacement_NN may_MD result_VB in_IN
        improvement_NN of_IN cognitive_JJ function_NN [_NN 19_CD ]_NN ._. The_DT mechanisms_NNS by_IN
        which_WDT estrogens_NNS protect_VBP neurons_NNS is_VBZ currently_RB under_IN intense_JJ
        investigation_NN and_CC may_MD involve_VB ,_, receptor-mediated_JJ mechanisms_NNS
        or_CC non-receptor-mediated_JJ antioxidative_JJ effects_NNS ._. For_IN these_DT
        reasons_NNS ,_, we_PRP assessed_VBD the_DT combined_VBN effects_NNS of_IN HIV_NNP proteins_NNS
        and_CC drugs_NNS of_IN abuse_NN ,_, methamphetamine_NN and_CC cocaine_NN on_IN neuronal_NN
        function_NN and_CC determined_VBN to_TO what_WP extent_NN estrogen_NN may_MD protect_VB
        against_IN these_DT neurotoxic_JJ substances_NNS ._.
      
      
        Results_NNS
        
          Detection_NNP of_IN estrogen_NN receptors_NNS and_CC dopaminergic_JJ
          neurons_NNS in_IN human_JJ fetal_JJ brain_NN cells_NNS
          Estrogen_NNP receptors_NNS were_VBD localized_JJ in_IN the_DT neuronal_NN
          cultures_NNS by_IN immunostaining_VBG and_CC by_IN mRNA_NN analysis_NN by_IN
          RT-PCR_NNP ._. We_PRP found_VBD that_IN 5_CD -_: 10_CD %_NN cells_NNS immunostained_JJ for_IN
          estrogen_NN receptors_NNS ._. Estrogen_NNP receptors_NNS could_MD be_VB localized_JJ
          in_IN both_DT neurons_NNS and_CC astrocytes_NNS (_( Figures_NNS 1_CD A_DT ,_, Band_NNP 2_CD D-F_NNP )_) ._.
          The_DT immunostaining_VBG was_VBD noted_VBN in_IN the_DT cytoplasm_NN and_CC nucleus_NN
          of_IN these_DT cells_NNS ._. mRNA_NN for_IN estrogen_NN receptor-α_JJ but_CC not_RB
          estrogen_NN receptor-β_JJ could_MD be_VB detected_VBN in_IN these_DT cultures_NNS
          (_( Figure_NN 3_LS )_) ._. Dopaminergic_NNP neurons_NNS were_VBD detected_VBN by_IN
          immunostaining_VBG for_IN dopamine_NN and_CC dopamine_NN transporter_NN
          which_WDT could_MD be_VB co-localized_JJ in_IN nearly_RB 60_CD %_NN neurons_NNS (_( Table_NNP
          1_CD ,_, Figures_NNS 2_CD A-C_NNP )_) as_RB well_RB as_IN dopamine_NN receptors_NNS :_: D_NNP 1_CD A_DT (_( 50_CD %_NN
          cells_NNS )_) and_CC D_NNP 2_CD (_( 40_CD %_NN cells_NNS )_) (_( Figures_NNS 2_CD E_NNP ,_, and_CC 2_CD F_NN )_) ._. Estrogen_NNP
          receptor_NN colocalized_JJ with_IN cells_NNS staining_VBG for_IN dopamine_NN
          (_( Figure_NN 1_CD A_DT )_) as_RB well_RB as_IN D_NNP 1_CD A_DT and_CC D_NNP 2_CD receptor_NN containing_VBG
          neurons_NNS (_( Figures_NNS 2_CD Eand_NNP 2_CD F_NN )_) ._.
        
        
          Blocking_NNP of_IN neurotoxicity_NN of_IN supernatants_NNS from_IN HIV_NNP
          infected_VBN monocytes_NNS with_IN antisera_NN to_TO gp_NN 120_CD and_CC Tat_NNP
          Cell_NNP culture_NN supernatants_NNS from_IN HIV_NNP infected_JJ monocytic_JJ
          cells_NNS were_VBD collected_VBN periodically_RB and_CC analyzed_VBD for_IN their_PRP$
          neurotoxic_JJ potential_NN ._. Maximum_NNP neurotoxicity_NN was_VBD noted_VBN at_IN
          two_CD weeks_NNS post_NN infection_NN (_( Figure_NN 4_CD A_DT )_) ._. Complete_JJ
          obliteration_NN of_IN neurotoxicity_NN was_VBD noted_VBN when_WRB the_DT
          supernatants_NNS were_VBD immunoabsorbed_JJ against_IN antisera_NN to_TO
          gp_NN 120_CD and_CC Tat_NNP (_( Figure_NN 4_CD B_NNP )_) ._. However_RB ,_, when_WRB immunoabsorbed_JJ
          against_IN each_DT of_IN the_DT antisera_NN alone_RB ,_, the_DT effect_NN on_IN
          neurotoxicity_NN of_IN the_DT culture_NN supernatants_NNS was_VBD not_RB
          significant_JJ (_( not_RB shown_VBN )_) ._.
        
        
          Neurotoxicity_NNP of_IN HIV_NNP proteins_NNS with_IN methamphetamine_NN
          or_CC cocaine_NN
          To_TO determine_VB the_DT synergistic_JJ neurotoxic_JJ properties_NNS of_IN
          the_DT viral_JJ proteins_NNS and_CC drugs_NNS of_IN abuse_NN ,_, we_PRP initially_RB
          conducted_VBD time_NN and_CC dose_NN response_NN curves_NNS for_IN each_DT compound_NN
          individually_RB and_CC then_RB in_IN combination_NN of_IN one_CD another_DT ._. We_PRP
          determined_VBD that_IN dosages_NNS for_IN causing_VBG neuronal_NN cell_NN death_NN
          or_CC changes_NNS in_IN mitochondrial_NN potential_JJ paralleled_JJ one_CD
          another_DT ,_, however_RB changes_VBZ in_IN mitochondrial_NN potential_NN could_MD
          be_VB seen_VBN as_RB early_RB as_IN 4_CD -_: 8_CD hours_NNS (_( Figure_NN 5_LS )_) ,_, significant_JJ
          cell_NN death_NN occurred_VBD at_IN 16_CD hrs_NNS post_NN treatment_NN ._. No_DT
          significant_JJ toxicity_NN was_VBD noted_VBN with_IN Tat_NNP <_NN 80_CD nM_NN ,_, gp_NN 120_CD
          <_NN 40_CD pM_NN ,_, or_CC Tat_NNP (_( 40_CD nM_NN )_) +_NN gp_NN 120_CD (_( 30_CD pM_NN )_) (_( Figure_NN 5_LS )_) ._.
          To_TO determine_VB the_DT specificity_NN of_IN Tat_NNP action_NN ,_, we_PRP used_VBD a_DT
          two_CD Tat_NNP deletion_NN mutants_NNS (_( TatΔ_NNP 31_CD -_: 61_CD and_CC TatΔ_NNP 48_CD -_: 56_CD )_) ._. No_DT
          changes_NNS in_IN neuronal_NN cell_NN death_NN were_VBD noted_VBN at_IN maximal_NN
          concentrations_NNS of_IN TatΔ_NNP 31_CD -_: 61_CD tested_VBN (_( 500_CD nM_NN )_) and_CC partial_JJ
          obliteration_NN of_IN neurotoxicity_NN was_VBD noted_VBN with_IN TatΔ_NNP 48_CD -_: 56_CD
          (_( Figure_NN 6_CD )_) ._. These_DT observations_NNS are_VBP consistent_JJ with_IN our_PRP$
          previous_JJ experience_NN with_IN synthetic_JJ Tat_NNP peptides_NNS
          demonstrating_VBG that_IN Tat_NNP 31_CD -_: 61_CD contains_VBZ the_DT neurotoxic_JJ
          epitope_NN [_NN 20_CD ]_NN ._. To_TO determine_VB the_DT specificity_NN of_IN gp_NN 120_CD
          action_NN we_PRP used_VBD a_DT non-specific_JJ glycoprotein_NN α_NN 2_CD -_: HS_NNP
          glycoprotein_NN ._. No_DT neurotoxicity_NN was_VBD detected_VBN at_IN the_DT
          highest_JJS concentrations_NNS tested_VBN (_( 1_CD μM_NN )_) ._.
          Similarly_RB ,_, no_DT significant_JJ neurotoxicity_NN was_VBD noted_VBN with_IN
          methamphetamine_NN <_NN 500_CD μM_NN (_( Figure_NN 5_CD A_DT )_) ._. In_IN addition_NN ,_, all_DT
          concentrations_NNS of_IN cocaine_NN tested_VBN were_VBD non-toxic_JJ by_IN these_DT
          assays_NNS ._. The_DT maximal_NN concentration_NN tested_VBN was_VBD 16_CD uM_NN ._. 40_CD nM_NN
          Tat_NNP +_NN 30_CD pM_NN gp_NN 120_CD with_IN cocaine_NN (_( 1_CD ._. 6_CD or_CC 16_CD μM_NN )_) or_CC
          methamphetamine_NN (_( 250_CD or_CC 500_CD μM_NN )_) produced_VBN significant_JJ (_( P_NN
          <_NN 0_CD ._. 05_CD )_) neuronal_NN cell_NN death_NN (_( Figure_NN 5_CD Aand_NNP 5_CD B_NNP )_) and_CC
          decreases_NNS in_IN mitochondrial_NN potential_JJ in_IN each_DT case_NN (_( Figure_NN
          5_CD C_NNP )_) ._. When_WRB 80_CD nM_NN Tat_NNP was_VBD combined_VBN with_IN either_DT 30_CD pM_NN gp_NN 120_CD ,_,
          500_CD μM_NN methamphetamine_NN or_CC 1_CD ._. 6_CD μM_NN cocaine_NN ,_, significant_JJ
          decreases_NNS in_IN mitochondrial_NN potential_JJ (_( P_NN <_NN 0_CD ._. 05_CD )_) were_VBD
          observed_VBN demonstrating_VBG a_DT synergistic_JJ neurotoxic_JJ response_NN
          between_IN the_DT viral_JJ proteins_NNS and_CC drugs_NNS of_IN abuse_NN ._. The_DT
          synergism_NN for_IN both_DT methamphetamine_NN and_CC cocaine_NN showed_VBD a_DT
          steep_JJ dose_NN response_NN suggesting_VBG an_DT "_'' all_DT or_CC none_NN "_''
          phenomenon_NN (_( Figure_NN 5_LS )_) ._.
        
        
          Protection_NNP against_IN HIV_NNP protein-induced_JJ
          mitochondrial_NN toxicity_NN by_IN 17_CD β-estradiol_JJ
          We_PRP determined_VBD the_DT ability_NN of_IN 17_CD β-estradiol_JJ to_TO protect_VB
          against_IN the_DT synergistic_JJ neurotoxicity_NN induced_VBN by_IN the_DT
          viral_JJ proteins_NNS alone_RB or_CC in_IN combination_NN with_IN cocaine_NN or_CC
          methamphetamine_NN ._. Nearly_RB complete_JJ attenuation_NN of_IN neuronal_NN
          cell_NN death_NN induced_VBN by_IN Tat_NNP +_NN gp_NN 120_CD was_VBD noted_VBN in_IN a_DT
          concentration_NN dependent_JJ manner_NN (_( Figure_NN 7_CD )_) ._. 1_LS nM_NN
          17_CD β-estradiol_JJ could_MD also_RB protect_VB against_IN the_DT combined_VBN
          synergistic_JJ neurotoxicity_NN of_IN the_DT viral_JJ proteins_NNS (_( Tat_NNP 40_CD
          nM_NN +_NN gp_NN 120_CD 30_CD pM_NN )_) with_IN cocaine_NN (_( 1_CD ._. 6_CD μM_NN )_) or_CC methamphetamine_NN
          (_( 500_CD μM_NN )_) (_( Figure_NN 8_CD )_) ._. 1_LS nM_NN 17_CD β-estradiol_JJ protected_VBN against_IN
          both_DT ,_, changes_NNS in_IN mitochondrial_NN membrane_NN potential_JJ (_( Figure_NN
          8_CD Aand_NNP 8_CD B_NNP )_) and_CC neuronal_NN cell_NN death_NN (_( Figure_NN 8_CD C_NNP )_) ._. However_RB ,_,
          this_DT toxicity_NN of_IN higher_JJR concentration_NN cocaine_NN (_( 16_CD μM_NN )_)
          could_MD be_VB only_RB partially_RB reversed_VBN by_IN 1_CD nM_NN 17_CD β-estradiol_JJ
          (_( Figure_NN 8_CD B_NNP )_) ._. A_DT lower_JJR concentration_NN of_IN 17_CD β-estradiol_JJ (_( 0_CD ._. 1_LS
          nM_NN )_) could_MD also_RB completely_RB reverse_VB the_DT changes_NNS in_IN
          mitochondrial_NN membrane_NN potential_JJ (_( Figure_NN 8_CD Aand_NNP 8_CD B_NNP )_) but_CC
          not_RB cell_NN death_NN (_( Figure_NN 7_CD )_) ._. To_TO determine_VB the_DT mechanism_NN of_IN
          estrogen_NN action_NN ,_, we_PRP pretreated_JJ the_DT cells_NNS with_IN either_DT ICI_NNP
          182_CD ,_, 780_CD (_( 1_CD μM_NN or_CC 10_CD μM_NN )_) or_CC tamoxifen_NN (_( 100_CD pM_NN ,_, 1_CD nM_NN )_) ._. We_PRP
          tried_VBD several_JJ different_JJ combinations_NNS and_CC concentrations_NNS
          of_IN viral_JJ proteins_NNS and_CC methamphetamine_NN or_CC cocaine_NN ._.
          Although_IN protection_NN with_IN 17_CD β-estradiol_JJ was_VBD consistently_RB
          present_JJ ,_, in_IN each_DT case_NN the_DT estrogen_NN antagonists_NNS failed_VBD to_TO
          reverse_VB the_DT protective_JJ effects_NNS of_IN 17_CD β-estradiol_JJ on_IN
          mitochondrial_NN membrane_NN potential_JJ (_( Figure_NN 8_CD Aand_NNP 8_CD B_NNP )_) ._.
          Interestingly_RB ,_, however_RB ,_, ICI_NNP 182_CD ,_, 780_CD ,_, a_DT prototypic_JJ
          estrogen_NN antagonist_NN ,_, blocked_VBD the_DT protective_JJ effect_NN of_IN
          17_CD β-estradiol_JJ on_IN neuronal_NN cell_NN death_NN (_( P_NN <_NN 0_CD ._. 05_CD )_) while_IN
          tamoxifen_NN had_VBD only_RB a_DT partial_JJ effect_NN that_WDT was_VBD not_RB
          significant_JJ (_( Figure_NN 8_CD D_NNP )_) ._. Both_DT ICI_NNP 182_CD ,_, 780_CD and_CC tamoxifen_NN
          alone_RB did_VBD not_RB produce_VB neurotoxicity_NN at_IN the_DT above_JJ
          concentrations_NNS (_( Figure_NN 8_CD D_NNP )_) ._.
        
      
      
        Discussion_NNP
        Although_IN it_PRP is_VBZ clear_JJ that_IN patients_NNS with_IN HIV_NNP infection_NN
        may_MD develop_VB dementia_NN and_CC non-_NN HIV_NNP infected_JJ drug_NN abusers_NNS
        develop_VBP evidence_NN for_IN neuronal_NN dysfunction_NN ,_, it_PRP is_VBZ not_RB
        clearly_RB established_VBN if_IN patients_NNS exposed_VBN to_TO both_DT HIV_NNP and_CC
        drugs_NNS of_IN abuse_NN are_VBP at_IN increased_VBN risk_NN for_IN neurological_JJ
        complications_NNS ._. In_IN this_DT study_NN ,_, we_PRP show_VBP that_IN HIV_NNP proteins_NNS may_MD
        synergize_NN with_IN drugs_NNS such_JJ as_IN methamphetamine_NN and_CC cocaine_NN to_TO
        cause_VB neurotoxicity_NN ._. These_DT findings_NNS are_VBP supported_VBN by_IN recent_JJ
        observations_NNS suggesting_VBG that_IN HIV_NNP infected_JJ drug_NN abusers_NNS have_VBP
        a_DT more_RBR severe_JJ encephalitis_NNS at_IN autopsy_NN [_NN 7_CD ,_, 8_CD ,_, 9_CD ]_NN and_CC at_IN
        least_JJS in_IN some_DT HIV_NNP infected_JJ drug_NN abusers_NNS an_DT accelerated_VBN form_NN
        of_IN HIV_NNP dementia_NN may_MD be_VB observed_VBN [_NN 21_CD ]_NN ._. One_CD possible_JJ cause_NN
        of_IN this_DT acceleration_NN may_MD be_VB the_DT synergistic_JJ neurotoxic_JJ
        properties_NNS of_IN HIV_NNP proteins_NNS and_CC the_DT drugs_NNS of_IN abuse_NN ._. Our_PRP$
        observations_NNS also_RB suggest_VBP that_IN an_DT acute_JJ exposure_NN may_MD be_VB
        sufficient_JJ to_TO cause_VB neurotoxicity_NN ._. The_DT mechanism_NN by_IN which_WDT
        these_DT substances_NNS synergize_NN remains_VBZ elusive_JJ ._. As_IN demonstrated_VBN
        in_IN these_DT studies_NNS ,_, at_IN least_JJS in_IN part_NN the_DT mechanism_NN involves_VBZ
        mitochondrial_NN dysfunction_NN ._. Since_IN both_DT gp_NN 120_CD and_CC Tat_NNP have_VBP
        been_VBN shown_VBN to_TO cause_VB toxicity_NN to_TO dopaminergic_JJ cells_NNS and_CC
        similarly_RB methamphetamine_NN and_CC cocaine_NN also_RB cause_VB toxicity_NN
        to_TO dopaminergic_JJ systems_NNS ,_, we_PRP characterized_VBD the_DT dopaminergic_JJ
        cell_NN types_NNS and_CC receptors_NNS in_IN our_PRP$ culture_NN system_NN ._. We_PRP found_VBD
        that_IN only_RB a_DT small_JJ proportion_NN of_IN these_DT cells_NNS underwent_VBD cell_NN
        death_NN when_WRB exposed_VBN to_TO the_DT proteins_NNS and_CC drugs_NNS of_IN abuse_NN
        suggesting_VBG that_IN there_EX must_MD be_VB another_DT susceptibility_NN factor_NN
        that_WDT characterizes_VBZ these_DT cells_NNS which_WDT needs_VBZ to_TO be_VB
        identified_VBN ._.
        We_PRP demonstrate_VBP that_IN HIV_NNP proteins_NNS gp_NN 120_CD and_CC Tat_NNP are_VBP
        important_JJ components_NNS in_IN supernatants_NNS of_IN HIV_NNP infected_JJ cells_NNS
        that_WDT cause_VBP neurotoxicity_NN ._. This_DT does_VBZ not_RB exclude_VB the_DT role_NN of_IN
        other_JJ substances_NNS such_JJ as_IN cytokines_NNS and_CC other_JJ soluble_JJ
        cellular_JJ products_NNS implicated_VBN in_IN neuropathogenesis_NNS of_IN HIV_NNP
        infection_NN ._. In_IN fact_NN previous_JJ studies_NNS have_VBP shown_VBN that_IN most_JJS of_IN
        these_DT substances_NNS can_MD be_VB induced_VBN by_IN HIV_NNP proteins_NNS in_IN
        uninfected_JJ monocytes_NNS and_CC astrocytes_NNS [_NN 14_CD ]_NN ._. Although_IN further_JJ
        studies_NNS are_VBP necessary_JJ to_TO determine_VB the_DT relative_JJ amounts_NNS and_CC
        kinetics_NNS of_IN HIV_NNP proteins_NNS released_VBN from_IN different_JJ HIV_NNP
        infected_JJ cells_NNS ,_, previous_JJ studies_NNS have_VBP shown_VBN that_IN both_DT gp_NN 120_CD
        and_CC Tat_NNP are_VBP present_JJ in_IN the_DT brains_NNS of_IN patients_NNS with_IN HIV_NNP
        dementia_NN and_CC encephalitis_NNS [_NN 15_CD ,_, 22_CD ]_NN ._. Gp_NNP 120_CD and_CC Tat_NNP may_MD also_RB
        synergize_NN to_TO cause_VB neurotoxicity_NN [_NN 15_CD ]_NN ._.
        Recently_RB ,_, much_JJ attention_NN has_VBZ been_VBN given_VBN to_TO the_DT
        neuroprotective_JJ properties_NNS of_IN estrogens_NNS for_IN both_DT chronic_JJ
        neurodegenerative_JJ diseases_NNS and_CC acute_JJ insults_NNS such_JJ as_IN
        stroke_NN ._. In_IN vitro_NN studies_NNS also_RB show_VBP that_IN estrogens_NNS can_MD
        protect_VB against_IN a_DT number_NN of_IN neurotoxic_JJ compounds_NNS [_NN 23_CD ]_NN ._. The_DT
        mechanisms_NNS by_IN which_WDT estrogens_NNS protect_VBP cells_NNS can_MD be_VB broadly_RB
        classified_VBN into_IN two_CD categories_NNS ,_, receptor_NN mediated_JJ and_CC
        non-receptor-mediated_JJ effects_NNS ._. Estrogen_NNP receptors_NNS are_VBP
        widely_RB expressed_VBN in_IN the_DT brain_NN with_IN some_DT regional_JJ
        differences_NNS [_NN 24_CD ]_NN ._. We_PRP initially_RB demonstrated_VBD the_DT presence_NN
        of_IN estrogen_NN receptors_NNS in_IN the_DT neuronal_NN cultures_NNS by_IN
        immunocytochemistry_NN and_CC determined_VBD their_PRP$ subtypes_NNS by_IN mRNA_NN
        analysis_NN ._. We_PRP found_VBD that_IN estrogen_NN receptors_NNS are_VBP localized_JJ
        both_DT in_IN neurons_NNS and_CC astrocytes_NNS ._. We_PRP also_RB found_VBD that_IN some_DT
        dopaminergic_JJ neurons_NNS co-expressed_JJ estrogen_NN receptors_NNS ._.
        We_PRP next_RB determined_VBN that_IN 17_CD β-estradiol_JJ at_IN concentrations_NNS
        that_WDT can_MD either_DT be_VB achieved_VBN physiologically_RB or_CC easily_RB
        obtained_VBN pharmacologically_RB protected_VBN against_IN the_DT combined_VBN
        insult_NN of_IN HIV_NNP proteins_NNS and_CC drug_NN abuse_NN ._. Protection_NNP was_VBD noted_VBN
        against_IN both_DT cell_NN death_NN and_CC mitochondrial_NN toxicity_NN ._. The_DT
        protection_NN was_VBD specific_JJ since_IN no_DT protection_NN was_VBD noted_VBN with_IN
        17_CD α-estradiol_JJ ._. In_IN subsequent_JJ experiments_NNS we_PRP determined_VBD if_IN
        this_DT protection_NN was_VBD mediated_JJ via_IN estrogen_NN receptors_NNS ._.
        Estrogen_NNP receptor_NN antagonist_NN ,_, ICI_NNP 182_CD ,_, 780_CD completely_RB ,_, and_CC
        tamoxifen_NN partially_RB reversed_VBD the_DT neuroprotective_JJ effects_NNS of_IN
        17_CD β-estradiol_JJ using_VBG cell_NN death_NN as_IN an_DT end_NN point_NN ._. However_RB
        these_DT compounds_NNS were_VBD unable_JJ to_TO reverse_VB the_DT neuroprotective_JJ
        effects_NNS of_IN estrogen_NN on_IN mitochondrial_NN potential_JJ ,_, suggesting_VBG
        that_IN the_DT mitochondrial_NN effects_NNS of_IN estrogen_NN are_VBP non-receptor_JJ
        mediated_JJ ._. Thus_RB the_DT toxic_JJ effects_NNS on_IN mitochondria_NN and_CC
        neuronal_NN cell_NN survival_NN seems_VBZ to_TO be_VB independently_RB regulated_VBN ._.
        However_RB ,_, it_PRP seems_VBZ that_IN 17_CD β-estradiol_JJ can_MD protect_VB against_IN
        both_DT these_DT effects_NNS by_IN receptor_NN and_CC non-receptor_JJ mediated_JJ
        mechanisms_NNS ._. These_DT observations_NNS are_VBP consistent_JJ with_IN recent_JJ
        reports_NNS showing_VBG that_IN 17_CD β-estradiol_JJ interacts_NNS directly_RB with_IN
        a_DT subunit_NN of_IN mitochondrial_NN F_NN 0_CD F_NN 1_CD -_: ATP_NNP synthase_NN /_NN ATPase_NNP
        required_VBD for_IN the_DT coupling_NN of_IN a_DT proton_NN gradient_NN across_IN the_DT
        F_NN 0_CD sector_NN of_IN the_DT enzyme_NN in_IN the_DT mitochondrial_NN membrane_NN to_TO
        ATP_NNP synthesis_NN in_IN the_DT F_NN 1_CD sector_NN of_IN the_DT enzyme_NN [_NN 25_CD ]_NN ._. This_DT
        accounts_NNS for_IN the_DT antioxidant_NN properties_NNS of_IN 17_CD β-estradiol_JJ ._.
        Due_JJ to_TO its_PRP$ multiple_JJ sites_NNS of_IN action_NN ,_, its_PRP$ wide_JJ spectrum_NN of_IN
        protection_NN against_IN multiple_JJ neurotoxic_JJ substances_NNS at_IN easily_RB
        obtainable_JJ concentrations_NNS and_CC the_DT ease_NN of_IN administration_NN of_IN
        estrogen_NN ,_, this_DT compound_NN is_VBZ a_DT very_RB attractive_JJ candidate_NN for_IN
        consideration_NN for_IN therapeutic_JJ intervention_NN in_IN HIV-infected_NNP
        drug_NN abusing_VBG women_NNS ._. Clinical_NNP trials_NNS are_VBP now_RB necessary_JJ to_TO
        confirm_VB these_DT observations_NNS ._. Caution_NN may_MD be_VB necessary_JJ in_IN the_DT
        use_NN of_IN estrogens_NNS in_IN this_DT population_NN ,_, because_IN estrogens_NNS have_VBP
        been_VBN associated_VBN with_IN a_DT small_JJ but_CC real_JJ risk_NN of_IN ischemic_JJ
        heart_NN disease_NN and_CC cerebral_JJ infarcts_NNS [_NN 26_CD ]_NN ._. Some_DT patients_NNS
        with_IN HIV_NNP infection_NN may_MD have_VB a_DT hypercoagulable_JJ state_NN and_CC may_MD
        be_VB at_IN increased_VBN risk_NN of_IN developing_VBG cerebral_JJ infarcts_NNS [_NN
        27_CD ]_NN ._.
        We_PRP conclude_VBP that_DT methamphetamine_NN and_CC cocaine_NN may_MD
        synergize_NN with_IN HIV_NNP proteins_NNS to_TO cause_VB neurotoxicity_NN and_CC
        resulting_VBG in_IN increased_VBN dysfunction_NN in_IN HIV_NNP infected_JJ drug_NN
        users_NNS ._. Caution_NN should_MD also_RB be_VB used_VBN in_IN the_DT use_NN of_IN other_JJ
        structurally_RB and_CC functionally_RB similar_JJ psychotropic_JJ drugs_NNS in_IN
        HIV_NNP infected_JJ patients_NNS ._. Estrogen_NNP may_MD be_VB neuroprotective_JJ in_IN
        this_DT population_NN acting_VBG through_IN receptor_NN and_CC non-receptor_JJ
        mediated_JJ mechanisms_NNS ._.
      
      
        Methods_NNP
        
          Cultures_NNP of_IN human_JJ brain_NN cells_NNS
          Brain_NNP specimens_NNS were_VBD obtained_VBN from_IN human_JJ fetuses_NNS of_IN
          12_CD -_: 14_CD weeks_NNS gestational_JJ age_NN with_IN consent_NN from_IN women_NNS
          undergoing_VBG elective_JJ termination_NN of_IN pregnancy_NN and_CC approval_NN
          by_IN the_DT University_NNP of_IN Kentucky_NNP Institutional_NNP Review_NNP Board_NNP ._.
          Neuronal_NNP cultures_NNS were_VBD prepared_VBN as_IN described_VBN previously_RB [_NN
          20_CD ,_, 28_CD ]_NN ._. Briefly_NNP ,_, the_DT cells_NNS were_VBD mechanically_RB
          dissociated_JJ ,_, suspended_VBN in_IN Opti-_NNP MEM_NNP with_IN 5_CD %_NN
          heat-inactivated_JJ fetal_JJ bovine_JJ serum_NN ,_, 0_CD ._. 2_CD %_NN N_NNP 2_CD supplement_NN
          (_( GIBCO_NNP )_) and_CC 1_CD %_NN antibiotic_JJ solution_NN (_( penicillin_NN G_NNP 10_CD
          4_CD units_NNS /_NN ml_NN ,_, streptomycin_NN 10_CD mg_NN /_NN ml_NN and_CC amphotericin_NN B_NNP 25_CD
          μg_NN /_NN ml_NN )_) and_CC plated_JJ in_IN flat_JJ bottom_NN 96_CD well_RB plates_NNS ._. The_DT
          cells_NNS were_VBD maintained_VBN in_IN culture_NN for_IN at_IN least_JJS one_CD month_NN
          before_IN conducting_VBG the_DT neurotoxicity_NN and_CC mitochondrial_NN
          experiments_NNS ._.
        
        
          Immunostaining_NNP
          Cells_NNP were_VBD plated_JJ and_CC cultured_JJ on_IN coverslips_NNS for_IN
          immunostaining_VBG ._. The_DT media_NNS was_VBD removed_VBN and_CC neuronal_NN
          cultures_NNS were_VBD fixed_VBN for_IN 30_CD minutes_NNS with_IN Zamboni_NNP 's_POS
          fixative_JJ [_NN 29_CD ]_NN at_IN room_NN temperature_NN ._. Receptor_NNP
          immunoreactivity_NN was_VBD determined_VBN using_VBG monoclonal_NN or_CC
          polyclonal_NN antisera_NN as_IN listed_VBN in_IN Table_NNP 1_CD ._. Cells_NNP were_VBD
          incubated_JJ in_IN blocking_VBG buffer_NN consisting_VBG of_IN 4_CD %_NN casein_NN
          (_( w_NN /_NN v_NN )_) and_CC 0_CD ._. 1_CD %_NN bovine_JJ serum_NN albumin_NN (_( w_NN /_NN v_NN )_) in_IN phosphate_NN
          buffered_JJ saline_NN (_( PBS_NNP )_) at_IN pH_NN 7_CD ._. 4_CD for_IN 30_CD min_NN ._. Cells_NNP were_VBD
          then_RB incubated_JJ in_IN primary_JJ antibody_NN diluted_VBN in_IN blocking_VBG
          buffer_NN for_IN at_IN 24_CD h_NN at_IN 4_CD °_NN C_NNP ._. Following_VBG three_CD washes_NNS in_IN PBS_NNP
          the_DT cells_NNS were_VBD incubated_JJ with_IN fluorochrome_NN conjugated_JJ
          secondary_JJ antisera_NN diluted_VBN in_IN blocking_VBG buffer_NN (_( Table_NNP 1_LS )_)
          for_IN one_CD hour_NN at_IN room_NN temperature_NN ._. To_TO determine_VB
          specificity_NN of_IN staining_VBG ,_, some_DT cells_NNS were_VBD incubated_JJ in_IN
          blocking_VBG buffer_NN without_IN primary_JJ antibody_NN ._. In_IN addition_NN ,_,
          the_DT specificity_NN of_IN particular_JJ antibodies_NNS was_VBD further_RBR
          confirmed_VBN by_IN demonstrating_VBG appropriate_JJ patterns_NNS of_IN
          subcellular_NN immunoreactivity_NN in_IN positive_JJ controls_NNS ,_, as_RB
          well_RB as_IN the_DT absence_NN of_IN immunoreactivity_NN in_IN negative_JJ
          controls_NNS ._. After_IN the_DT final_JJ wash_NN ,_, the_DT coverslips_NNS containing_VBG
          cells_NNS were_VBD air_NN dried_VBD in_IN the_DT dark_JJ and_CC mounted_VBD on_IN slides_NNS
          with_IN ProLong_NNP ™_NN Antifade_NNP mounting_VBG media_NNS (_( Sakura_NNP Finitek_NNP
          USA_NNP ,_, Torrence_NNP ,_, CA_NNP )_) ._. They_PRP were_VBD maintained_VBN in_IN the_DT dark_JJ and_CC
          at_IN 4_CD °_NN C_NNP until_IN examined_VBD ._.
        
        
          Combined_VBN detection_NN of_IN estrogen_NN receptors_NNS and_CC
          dopaminergic_JJ systems_NNS
          Neuronal_NNP cultures_NNS plated_JJ on_IN coverslips_NNS were_VBD initially_RB
          treated_VBN as_IN described_VBN above_IN to_TO detect_VB estrogen_NN receptors_NNS ._.
          Cell_NNP were_VBD fixed_VBN in_IN Zamboni_NNP 's_POS solution_NN ,_, rinsed_JJ 3_CD -_: fold_VB in_IN
          PBS_NNP ,_, and_CC incubated_JJ with_IN mouse_NN anti-_NN ERα_NNP or_CC ERβ_NNP monoclonal_NN
          antibodies_NNS (_( 1_CD :_: 10_CD dilution_NN )_) for_IN at_IN least_JJS 1_CD h_NN at_IN room_NN
          temperature_NN ._. Anti_NNP mouse_NN IgG_NNP conjugated_JJ to_TO Cy_NNP 3_CD
          fluorochrome_NN (_( 1_CD :_: 250_CD dilution_NN ,_, 1_CD h_NN at_IN room_NN temperature_NN )_)
          was_VBD used_VBN to_TO visualize_VB ER_NNP antigenicity_NN (_( Jackson_NNP
          ImmunoResearch_NNP ,_, West_NNP Grove_NNP ,_, PA_NNP )_) ._. To_TO detect_VB dopamine_NN (_( DA_NNP )_) ,_,
          dopamine_NN receptors_NNS D_NNP 1_CD A_DT and_CC D_NNP 2_CD ,_, cells_NNS were_VBD incubated_JJ in_IN
          rabbit_NN polyclonal_NN antibodies_NNS (_( see_VB table_NN )_) overnight_JJ at_IN
          4_CD °_NN C_NNP ._. For_IN detection_NN of_IN dopamine_NN transporter_NN (_( DAT_NNP )_) rat_NN
          monoclonal_NN antisera_NN were_VBD used_VBN ._. Cells_NNP were_VBD then_RB incubated_JJ
          in_IN goat_NN anti_NN rabbit_NN IgG_NNP (_( 1_CD :_: 250_CD dilution_NN )_) conjugated_JJ to_TO
          DTAF_NNP for_IN 1_CD h_NN at_IN room_NN temperature_NN ._. Cells_NNP were_VBD washes_NNS three_CD
          times_NNS with_IN PBS_NNP ._. After_IN the_DT final_JJ wash_NN ,_, the_DT coverslips_NNS
          containing_VBG cells_NNS were_VBD air_NN dried_VBD in_IN the_DT dark_JJ and_CC
          coverslipped_JJ with_IN ProLong_NNP ™_NN Antifade_NNP mounting_VBG media_NNS
          (_( Sakura_NNP Finitek_NNP USA_NNP ,_, Torrence_NNP ,_, CA_NNP )_) ._. They_PRP were_VBD maintained_VBN
          in_IN the_DT dark_JJ and_CC at_IN 4_CD °_NN C_NNP until_IN examined_VBD ._.
          The_DT reaction_NN was_VBD visualized_JJ using_VBG fluorescence_NN
          microscopy_NN (_( Nikon_NNP Diaphot_NNP )_) and_CC images_NNS acquired_VBD using_VBG a_DT
          Spot_NNP 2_CD digital_JJ camera_NN (_( Diagnostic_NNP Instruments_NNP ,_, Sterling_NNP
          Heights_NNP ,_, MI_NNP )_) ._. Digital_NN images_NNS incorporating_VBG multiple_JJ
          fluorochromes_NNS (_( red_JJ and_CC green_JJ )_) were_VBD overlaid_VBN in_IN Photoshop_NNP
          5_CD ._. 0_CD (_( Adobe_NNP )_) ._.
        
        
          RT-PCR_NNP for_IN estrogen_NN receptors_NNS
          
            PCR_NNP amplification_NN ._.
            We_PRP utilized_JJ well_RB characterized_VBN RT-PCR_NNP methods_NNS to_TO
            determine_VB relative_JJ changes_NNS in_IN gene_NN expression_NN at_IN the_DT
            mRNA_NN level_NN ._. For_IN each_DT gene_NN examined_VBD ,_, we_PRP generated_VBD
            standard_JJ curves_NNS of_IN input_NN RNA_NNP and_CC cycle_NN number_NN to_TO
            determine_VB the_DT optimum_JJ cycle_NN number_NN within_IN the_DT linear_JJ
            range_NN for_IN PCR_NNP amplification_NN (_( data_NNS not_RB shown_VBN )_) ;_: for_IN all_DT
            genes_NNS examined_VBD ,_, this_DT was_VBD determined_VBN to_TO be_VB between_IN 25_CD -_: 30_CD
            cycles_NNS ._. These_DT methods_NNS have_VBP been_VBN validated_JJ in_IN studies_NNS
            showing_VBG that_IN ,_, within_IN the_DT optimal_NN range_NN of_IN
            amplification_NN ,_, yields_NNS of_IN PCR_NNP product_NN are_VBP linear_JJ with_IN
            respect_NN to_TO input_NN RNA_NNP [_NN 30_CD ]_NN ._.
            For_IN each_DT gene_NN ,_, stock_NN solutions_NNS were_VBD prepared_VBN
            containing_VBG 1_CD ._. 5_CD mM_NN MgCl_NNP 
            2_CD ,_, 1_CD X_NNP reaction_NN buffer_NN ,_, 10_CD μCi_NN of_IN
            32_CD P-_NNP dCTP_NN (_( 3000_CD Ci_NNP /_NN mmol_NN )_) (_( NEN_NNP ,_, Boston_NNP ,_, MA_NNP )_) ,_, 1_CD μM_NN each_DT
            primer_NN ,_, and_CC 1_CD ._. 5_CD U_NNP of_IN Taq_NNP polymerase_NN (_( Life_NNP
            Technologies_NNPS )_) ._. For_IN 
            ERα_NNP and_CC 
            ERβ_NNP PCR_NNP ,_, 1_CD ._. 5_CD U_NNP of_IN Taq_NNP Ab_NNP (_( Life_NNP
            Technologies_NNPS )_) was_VBD included_VBN in_IN each_DT reaction_NN ._. The_DT stock_NN
            solution_NN was_VBD aliquoted_JJ (_( 49_CD μl_NN /_NN tube_NN )_) ,_, and_CC 1_CD /_NN 30_CD of_IN
            synthesized_JJ cDNA_NN (_( from_IN reverse_NN transcription_NN reaction_NN )_)
            was_VBD added_VBN to_TO each_DT sample_NN tube_NN ._. Samples_NNP were_VBD then_RB
            thermocycled_JJ for_IN PCR_NNP amplification_NN (_( Hybaid_NNP ,_, Touchdown_NNP
            Thermocycler_NNP ,_, Middlesex_NNP ,_, United_NNP Kingdom_NNP )_) according_VBG to_TO
            the_DT following_VBG reaction_NN conditions_NNS :_: 1_CD min_NN 95_CD °_NN C_NNP ,_, 1_CD min_NN
            55_CD °_NN C_NNP ,_, 2_CD min_NN 72_CD °_NN C_NNP (_( 25_CD -_: 30_CD cycles_NNS )_) ._. After_IN amplification_NN ,_,
            PCR_NNP products_NNS were_VBD resolved_VBN by_IN polyacrylamide_NN gel_NN
            electrophoresis_NNS ._. The_DT gels_NNS were_VBD dried_VBN and_CC the_DT products_NNS
            were_VBD visualized_JJ and_CC quantified_VBN using_VBG a_DT PhosphorImager_NNP
            (_( Molecular_NNP Dynamics_NNP ,_, Sunnyvale_NNP ,_, CA_NNP )_) ._.
            All_DT the_DT oligonucleotide_NN sequence_NN pairs_NNS used_VBN for_IN gene_NN
            amplification_NN in_IN this_DT study_NN generated_VBD PCR_NNP products_NNS of_IN
            expected_VBN sizes_NNS that_WDT have_VBP been_VBN sequenced_JJ to_TO verify_VB their_PRP$
            identities_NNS :_: 
            L_NNP 27_CD A_DT sense_NN primer_NN :_:
            5_CD '_POS -_: ATGCTAACTGTCCAAGTCTA-_NNP 3_CD '_POS and_CC antisense_NN primer_NN
            5_CD '_POS -_: GGGAGCAACTCCATTCTTGT-_NNP 3_CD '_POS (_( 214_CD bp_NN )_) [_NN 31_CD ]_NN ;_: 
            ERα_NNP sense_NN primer_NN
            5_CD '_POS -_: AATTCTGACAATCGACGCCAG-_NNP 3_CD '_POS and_CC antisense_NN primer_NN
            5_CD '_POS -_: GTGCTTCAACATTCTCCCTCCTC-_NNP 3_CD '_POS (_( 344_CD bp_NN )_) [_NN 32_CD ]_NN ._.
          
        
        
          Infection_NNP of_IN monocytic_JJ cells_NNS with_IN HIV_NNP
          THP-_NNP 1_CD cells_NNS were_VBD cultured_JJ in_IN RPMI_NNP +_NN 10_CD %_NN fetal_JJ bovine_JJ
          serum_NN and_CC infected_VBN with_IN HIV-AdaM_NNP strain_NN at_IN an_DT MOI_NNP of_IN 100_CD ._.
          The_DT high_JJ MOI_NNP was_VBD chosen_VBN to_TO ensure_VB maximal_NN production_NN of_IN
          viral_JJ proteins_NNS ._. Culture_NNP supernatants_NNS were_VBD collected_VBN every_DT
          four_CD days_NNS by_IN half_NN media_NNS exchange_VBP and_CC frozen_VBN at_IN -_: 80_CD °_NN C_NNP till_IN
          used_VBN for_IN neurotoxicity_NN assays_NNS ._. For_IN immunoabsorption_NN of_IN
          viral_JJ proteins_NNS ,_, the_DT culture_NN supernatants_NNS were_VBD incubated_JJ
          for_IN 60_CD min_NN with_IN protein_NN A_DT beads_NNS conjugated_JJ with_IN
          polyclonal_NN antisera_NN to_TO either_CC Tat_NNP or_CC gp_NN 120_CD with_IN constant_JJ
          shaking_VBG at_IN room_NN temperature_NN ._. Following_VBG centrifugation_NN ,_,
          the_DT supernatants_NNS were_VBD removed_VBN and_CC immediately_RB used_VBN for_IN
          neurotoxicity_NN assays_NNS ._.
        
        
          Recombinant_NNP Tat_NNP and_CC gp_NN 120_CD proteins_NNS
          Recombinant_NNP Tat_NNP was_VBD prepared_VBN as_IN described_VBN previously_RB [_NN
          33_CD ]_NN with_IN minor_JJ modifications_NNS ._. The_DT 
          tat_NN gene_NN encoding_VBG the_DT first_JJ 72_CD
          amino_JJ acids_NNS were_VBD amplified_VBN from_IN HIV_NNP 
          BRU_NNP obtained_VBD from_IN Dr_NNP ._. Richard_NNP Gaynor_NNP
          through_IN the_DT AIDS_NNP repository_NN at_IN the_DT NIH_NNP and_CC inserted_VBN into_IN
          an_DT 
          E_NNP ._. coli_NNS vector_NN PinPoint_NNP Xa-_NNP 2_CD
          (_( Promega_NNP )_) ._. Two_CD deletion_NN mutants_NNS from_IN this_DT plasmid_NN were_VBD
          also_RB prepared_VBN ._. One_CD by_IN deleting_VBG the_DT sequence_NN encoding_VBG
          amino_JJ acids_NNS 31_CD -_: 61_CD of_IN Tat_NNP previously_RB shown_VBN to_TO contain_VB the_DT
          neurotoxic_JJ epitope_NN [_NN 20_CD ]_NN ._. Another_DT one_CD was_VBD prepared_VBN by_IN
          deleting_VBG the_DT sequences_NNS 48_CD -_: 56_CD encoding_VBG the_DT basic_JJ region_NN of_IN
          Tat_NNP ._. These_DT constructs_NNS allowed_VBD the_DT expression_NN of_IN the_DT Tat_NNP
          proteins_NNS as_IN a_DT fusion_NN protein_NN naturally_RB biotinylated_JJ at_IN
          the_DT N-_NNP terminus_JJ ._. The_DT biotinylated_JJ Tat_NNP proteins_NNS were_VBD
          purified_JJ on_IN a_DT column_NN of_IN soft_JJ release_NN avidin_NN resin_NN ,_,
          cleaved_JJ from_IN the_DT fusion_NN protein_NN using_VBG factor_NN Xa_NNP and_CC
          eluted_JJ from_IN the_DT column_NN followed_VBN by_IN desalting_VBG with_IN a_DT PD_NNP 10_CD
          column_NN ._. All_DT purification_NN steps_NNS contained_VBD dithiothreitol_NN
          to_TO prevent_VB oxidation_NN of_IN the_DT proteins_NNS ._. Tat_NNP proteins_NNS were_VBD
          >_NN 95_CD %_NN pure_JJ as_IN determined_VBN by_IN SDS-PAGE_NNP followed_VBN by_IN silver_NN
          staining_VBG ,_, and_CC analysis_NN by_IN HPLC_NNP using_VBG a_DT C_NNP 4_CD column_NN showed_VBD a_DT
          single_JJ symmetrical_JJ peak_NN ._. Western_JJ blot_NN analysis_NN showed_VBD
          that_IN these_DT preparations_NNS contained_VBD both_DT monomeric_JJ and_CC
          dimeric_JJ forms_NNS of_IN Tat_NNP 1_CD -_: 72_CD but_CC monomeric_JJ form_NN only_RB for_IN
          TatΔ_NNP 31_CD -_: 61_CD and_CC TatΔ_NNP 48_CD -_: 56_CD ._. The_DT functional_JJ activity_NN of_IN
          Tat_NNP 1_CD -_: 72_CD was_VBD confirmed_VBN using_VBG a_DT transactivation_NN assay_NN in_IN
          HL_NNP 3_CD T_NN 1_CD cells_NNS containing_VBG an_DT HIV-_NNP 1_CD LTR-CAT_NNP construct_VB [_NN 33_CD ]_NN ._.
          gp_NN 120_CD from_IN HIV_NNP 
          SF_NNP 2_CD was_VBD obtained_VBN as_IN a_DT gift_NN from_IN Chiron_NNP
          Corporation_NNP ._. Recombinant_NNP gp_NN 120_CD was_VBD made_VBN in_IN a_DT chinese_NN
          hamster_NN ovary_JJ cell_NN line_NN and_CC purification_NN yielded_VBD a_DT
          product_NN that_WDT was_VBD 95_CD %_NN gp_NN 120_CD with_IN the_DT remainder_NN being_VBG break_NN
          down_RB products_NNS of_IN gp_NN 120_CD as_IN determined_VBN by_IN western_JJ blot_NN
          analysis_NN ._. The_DT Tat_NNP and_CC gp_NN 120_CD preparations_NNS contained_VBD <_NN 1_CD
          pg_NN /_NN ml_NN endotoxin_NN as_IN determined_VBN using_VBG a_DT Pyrochrome_NNP
          Chromogenic_NNP test_NN kit_NN (_( Associates_NNPS of_IN Cape_NNP Cod_NNP Inc_NNP ._. ,_,
          Falmouth_NNP ,_, MA_NNP ._. )_) ._. The_DT Tat_NNP proteins_NNS were_VBD stored_VBN in_IN a_DT
          lyophilized_JJ form_NN and_CC gp_NN 120_CD as_IN a_DT stock_NN solution_NN in_IN water_NN
          at_IN -_: 80_CD °_NN C_NNP in_IN endotoxin-free_JJ siliconized_JJ microfuge_NN tubes_NNS
          until_IN taken_VBN for_IN experimentation_NN ._. Tat_NNP and_CC gp_NN 120_CD were_VBD
          highly_RB susceptible_JJ to_TO degradation_NN and_CC loss_NN of_IN biological_JJ
          activity_NN with_IN each_DT freeze-thaw_JJ cycle_NN ._. Therefore_RB ,_, single_JJ
          aliquots_NNS were_VBD used_VBN for_IN each_DT experiment_NN with_IN the_DT remaining_VBG
          solutions_NNS discarded_VBN ._.
        
        
          Neurotoxicity_NNP Assay_NNP
          At_IN the_DT time_NN of_IN experimental_JJ treatment_NN ,_, the_DT culture_NN
          media_NNS was_VBD replaced_VBN with_IN Locke_NNP 's_POS buffer_NN containing_VBG (_( in_IN mM_NN )_)
          154_CD NaCl_NNP ,_, 5_CD ._. 6_CD KCl_NNP ,_, 2_CD ._. 3_CD CaCl_NNP 
          2_CD ,_, 1_CD MgCl_NNP 
          2_CD ,_, 3_CD ._. 6_CD NaHCO_NNP 
          3_CD ,_, 5_CD glucose_NN ,_, 5_CD
          N-_NNP 2_CD -_: hydroxyethylpiperazine-_NN N_NNP '_POS -_: 2_CD -_: ethanesulfonic_JJ acid_NN (_( pH_NN
          7_CD ._. 2_LS )_) and_CC neurons_NNS were_VBD incubated_JJ with_IN culture_NN supernatants_NNS
          from_IN HIV_NNP infected_JJ monocytic_JJ cells_NNS ,_, subtoxic_JJ
          concentrations_NNS of_IN Tat_NNP (_( 40_CD nM_NN )_) +_NN gp_NN 120_CD (_( 30_CD pM_NN )_) ,_, various_JJ
          concentrations_NNS of_IN methamphetamine_NN or_CC cocaine_NN ,_, or_CC viral_JJ
          proteins_NNS +_NN methamphetamine_NN and_CC cocaine_NN ._. To_TO determine_VB the_DT
          specificity_NN of_IN action_NN of_IN the_DT viral_JJ proteins_NNS ,_, Tat_NNP 1_CD -_: 72_CD was_VBD
          compared_VBN to_TO TatΔ_NNP 31_CD -_: 61_CD and_CC TatΔ_NNP 48_CD -_: 56_CD at_IN 500_CD nM_NN
          concentration_NN each_DT ._. Similarly_RB ,_, gp_NN 120_CD (_( 500_CD pM_NN )_) was_VBD
          compared_VBN to_TO a_DT non-specific_JJ glycoprotein_NN α_NN 2_CD -_: HS_NNP
          glycoprotein_NN (_( Sigma_NNP ;_: 1_CD uM_NN )_) ._. Cell_NNP death_NN in_IN each_DT case_NN was_VBD
          monitored_VBN by_IN trypan_NN blue_JJ exclusion_NN 15_CD hours_NNS later_RB as_IN
          described_VBN previously_RB [_NN 20_CD ,_, 28_CD ]_NN ._. Neuronal_NNP cell_NN counts_NNS were_VBD
          determined_VBN from_IN five_CD fields_NNS at_IN predetermined_VBN coordinate_VB
          locations_NNS ._. Each_DT field_NN was_VBD photographed_VBN ,_, coded_VBN and_CC
          counted_VBN ._. At_IN least_JJS 200_CD cells_NNS were_VBD counted_VBN in_IN each_DT field_NN ._.
          Each_DT experiment_NN was_VBD conducted_VBN in_IN triplicate_NN wells_NNS and_CC at_IN
          least_JJS three_CD independent_JJ experiments_NNS were_VBD conducted_VBN with_IN
          each_DT pharmacological_JJ agent_NN ._. The_DT means_VBZ and_CC standard_JJ errors_NNS
          of_IN the_DT mean_NN were_VBD calculated_VBN and_CC data_NNS were_VBD analyzed_VBN by_IN
          ANOVA_NNP with_IN Tukey-_NNP Kramer_NNP post-hoc_JJ comparisons_NNS ._. To_TO
          investigate_VB the_DT neuroprotective_JJ properties_NNS of_IN estrogen_NN ,_,
          the_DT cells_NNS were_VBD incubated_JJ with_IN 17_CD β-estradiol_JJ (_( Sigma_NNP )_) at_IN
          various_JJ concentrations_NNS followed_VBN by_IN exposure_NN to_TO the_DT viral_JJ
          proteins_NNS and_CC /_NN or_CC the_DT drugs_NNS of_IN abuse_NN in_IN Locke_NNP 's_POS buffer_NN and_CC
          cell_NN death_NN monitored_VBN as_IN described_VBN above_IN ._. Preincubation_NNP
          with_IN 17_CD β-estradiol_JJ in_IN each_DT case_NN was_VBD <_NN 5_CD min_NN ._. To_TO
          determine_VB the_DT mechanism_NN of_IN estrogen_NN protection_NN ,_, the_DT
          cultures_NNS were_VBD incubated_JJ with_IN either_DT ICI_NNP 182_CD ,_, 780_CD (_( 100_CD nM_NN )_)
          (_( Tocris_NNP )_) or_CC tamoxifen_NN (_( 10_CD nM_NN )_) (_( Sigma_NNP )_) ._.
        
        
          Measurement_NNP of_IN mitochondrial_NN membrane_NN potential_JJ
          activity_NN
          To_TO determine_VB the_DT effect_NN of_IN the_DT viral_JJ proteins_NNS on_IN
          mitochondrial_NN function_NN ,_, we_PRP used_VBD a_DT fluorescent_NN dye_NN JC-_NNP 1_CD to_TO
          measure_VB changes_NNS in_IN mitochondrial_NN membrane_NN potential_JJ ._. Once_RB
          loaded_VBN into_IN the_DT mitochondria_NN ,_, JC-_NNP 1_CD undergoes_NNS aggregate_JJ
          formation_NN in_IN the_DT regions_NNS of_IN high_JJ potential_NN ._. The_DT resulting_VBG
          spectral_NN shift_NN of_IN the_DT dye_NN can_MD be_VB used_VBN to_TO detect_VB changes_NNS
          in_IN mitochondrial_NN activity_NN ._. The_DT green_JJ fluorescent_NN JC-_NNP 1_CD
          (_( 5_CD ,_, 5_CD '_POS ,_,
          6_CD ,_, 6_CD '_POS -_: tetrachloro-_NN 1_CD ,_, 1_CD '_POS ,_, 3_CD ,_, 3_CD '_POS -_: tetraethylbenzimidazolylcabocyanine_NN
          iodine_NN ,_, T-_NNP 3168_CD )_) exist_VB as_IN a_DT monomer_NN at_IN low_JJ membrane_NN
          potential_JJ ._. However_RB ,_, at_IN higher_JJR potentials_NNS ,_, JC-_NNP 1_CD forms_NNS red_JJ
          fluorescent_NN "_'' J-_NNP aggregates_NNS "_'' that_DT exhibit_NN broad_JJ spectrum_NN
          and_CC an_DT emission_NN maximum_NN at_IN 590_CD nm_NN ._. Optical_NNP filters_NNS
          designed_VBN for_IN fluorescein_NN and_CC tetramethylrhodamine_NN were_VBD
          used_VBN to_TO separately_RB visualize_VB the_DT monomer_NN and_CC J-_NNP aggregate_JJ
          forms_NNS ,_, respectively_RB ._. Mitochondrial_NNP function_NN was_VBD monitored_VBN
          following_VBG treatment_NN with_IN the_DT above_JJ compounds_NNS at_IN different_JJ
          concentrations_NNS and_CC time_NN points_NNS ._. Briefly_NNP ,_, after_IN experiment_NN
          treatment_NN cells_NNS were_VBD incubated_JJ for_IN 30_CD minutes_NNS at_IN 37_CD °_NN C_NNP in_IN
          a_DT 5_CD %_NN CO_NNP 
          2_CD incubator_NN in_IN the_DT presence_NN of_IN 10_CD μM_NN
          of_IN the_DT JC-_NNP 1_CD and_CC then_RB washed_VBN in_IN Locke_NNP 's_POS solution_NN ._.
          Optical_NNP measurements_NNS were_VBD acquired_VBN with_IN excitation_NN at_IN
          485_CD nm_NN and_CC emission_NN at_IN 527_CD nm_NN ,_, and_CC 590_CD nm_NN ._. The_DT levels_NNS of_IN
          fluorescence_NN at_IN both_DT emission_NN wavelengths_NNS were_VBD quantified_VBN
          and_CC ratio_NN of_IN measurements_NNS was_VBD assessed_VBN ._. The_DT pertinent_JJ
          data_NN are_VBP given_VBN as_IN mean_NN ±_NN S_NNP ._. E_NNP ._. M_NNP ._. for_IN mean_NN optical_JJ
          measurements_NNS ._. The_DT values_NNS are_VBP expressed_VBN as_IN percent_NN of_IN the_DT
          mean_JJ control_NN values_NNS ±_NN S_NNP ._. E_NNP ._. M_NNP ._. and_CC analyzed_VBD using_VBG
          ANOVA_NNP ._.
        
      
    
  
